Margenza (margetuximab or margetuximab-cmkb) is a targeted anticancer treatment for metastatic, HER2-positive breast cancer that has spread to other areas of the body. It’s typically used when you’ve already tried a few other similar targeted treatments before. Margenza (margetuximab) is an infusion through your veins, and it’s used together with other anticancer medications in your treatment plan.
Metastatic, HER2-positive breast cancer
Margenza (margetuximab) is a monoclonal antibody that acts as a human epidermal growth factor receptor 2 (HER2) inhibitor. It blocks a specific protein in the body that’s important for cell growth called HER2. HER2 is found on both normal and cancer cells. Cancer cells usually have more HER2 proteins than normal cells. This can cause cancer cells to grow more quickly than normal cells. When HER2 is blocked by Margenza (margetuximab), cancer cells can’t grow and spread as well.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Treatment option for people who’ve tried at least two other HER2-targeted regimens before
More precise in the way it targets cancer cells compared to traditional chemotherapy
Given every 3 weeks
After the first infusion, it can be given over a short amount of time (30 minutes).
Can cause heart problems like heart failure and requires regular monitoring of heart function
Requires administration by a healthcare provider in an infusion center
Not safe during pregnancy since it can harm an unborn baby
You might experience a reaction during or shortly after your Margenza (margetuximab) infusion. Let your provider know right away if you experience any infusion reactions like fever, chills, dizziness, headache, nausea, sweating, rash, or trouble breathing.
Each infusion appointment can take a few hours because it includes the time it takes to check in, get your infusion of Margenza (margetuximab) and possibly other anticancer treatment, and monitor for side effects. Make sure you have what you need to be comfortable during that time. Wear sleeves that are easy to roll up, bring a water bottle to help you stay hydrated, and bring a snack.
You’ll need regular monitoring of your heart during your Margenza (margetuximab) treatment and possibly when you finish therapy. This is because the medication can cause heart failure. Make sure to let your provider know right away if you experience any new or worsening shortness of breath, cough, swelling of your legs or feet, sudden weight gain, or dizziness. These can be signs of heart failure and you might need to stop taking this medication.
If you’re a female who can get pregnant, use birth control while receiving Margenza (margetuximab) and for at least 4 months after your last dose. This medication can cause harm to an unborn baby. Contact your provider know right away if you become pregnant during Margenza (margetuximab) treatment.
Margenza (margetuximab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Margenza (margetuximab) can cause new or worsening heart failure and affect how well your heart pumps blood through your body. Make sure your provider has your full medical history, so they can closely monitor your heart through imaging using an echocardiogram or a MUGA scan. You’ll need to get this scan before starting treatment and about every 3 months while receiving Margenza (margetuximab). Let your care team know if you experience any signs and symptoms of heart failure, including shortness of breath; dry cough; swelling of legs, arms, or face; irregular heartbeats; dizziness; or rapid weight gain.
Margenza (margetuximab) might cause harm to an unborn baby. If you're a female of childbearing age receiving Margenza (margetuximab), your provider might check to see if you’re pregnant before you start treatment. If you’re female who is able to become pregnant, use birth control while you’re receiving Margenza (margetuximab) and for at least 4 months after your last dose. Let your provider know right away if you become pregnant during this time.
People receiving Margenza (margetuximab) might experience infusion reactions. Symptoms include fever, chills, dizziness, headache, nausea, sweating, rash, or trouble breathing. Most of the reactions happened during the first infusion and went away within 1 day. If a reaction occurs, your healthcare provider can slow down the infusion and help manage or treat the symptom. To lower your risk of future reactions, your provider might also give you other medications (like antihistamines or corticosteroids) before your next infusions. Alert your provider or get medical help right away if you experience any symptom of an infusion reaction.
Your healthcare provider will determine your dose of Margenza (margetuximab) based on your body weight.
The typical dose is 15 mg/kg injected into the veins (intravenously or IV) by a provider every 3 weeks.
HER2-positive, breast cancers - IV and SQ injections
HER2-positive, metastatic stomach cancer - IV injection only
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.